FAQs About Weight-Loss Medications
Weight loss treatment often raises just as many questions as weight management itself. From wondering whether you’re a candidate for medication to understanding how quickly results may occur, managing side effects, and knowing what lifestyle changes are still important, it’s common to have questions throughout your weight loss journey.
This FAQ answers many of the questions our providers hear most often. While every treatment plan is personalized, these answers can help you better understand what to expect, how to use your treatment safely and effectively, and when you should contact your healthcare provider.
Is obesity really a disease?
Yes. Obesity is a chronic, relapsing disease influenced by biological, genetic, hormonal, environmental, behavioral, and social factors. It is not simply a lack of willpower.
How do GLP-1 medicines cause weight loss?
They reduce hunger and cravings, increase fullness, slow gastric emptying, and improve glucose-dependent metabolic signaling. Tirzepatide also activates the GIP receptor.
Which medication produces the most weight loss?
In the 72-week SURMOUNT-5 head-to-head trial in adults with obesity without diabetes, tirzepatide produced greater average weight loss than semaglutide at maximum tolerated doses—about 20% versus 14%. Individual response, safety, access, and indication still determine the best choice.
What is retatrutide?
Retatrutide is Eli Lilly’s investigational weekly GLP-1/GIP/glucagon triple agonist. Phase 3 topline results reported 28.3% average loss at 80 weeks at 12 mg, with approximately 30.3% reported at 104 weeks in a higher-BMI extension. It is not FDA-approved and should not be purchased as an online research peptide.
Why am I not losing weight yet?
Introductory doses are mainly for tolerability. Some patients respond immediately; others need several dose increases and may not see meaningful loss for four or five months. A minority do not respond adequately.
Should my dose increase every month?
Not automatically. The dose may be held when weight loss is appropriate, appetite is controlled, or side effects continue. The goal is the lowest effective tolerated dose—not reaching the maximum as quickly as possible.
My friend lost weight in the first week. Why didn’t I?
People differ in medication, dose, body composition, diabetes status, genetics, diet, sleep, activity, other medicines, and sensitivity to appetite hormones. Another person’s response does not predict yours.
What if I miss doses?
Follow the product instructions and contact APNS after a prolonged interruption. Restarting a high dose may cause severe GI effects, so re-titration may be needed.
What should I do if I have not had a bowel movement for two days?
Contact APNS and use the previously approved bowel plan. Hydration, gradual fiber, and an appropriate osmotic laxative may help. Severe discomfort, vomiting, swelling, or inability to pass gas requires urgent evaluation—not more fiber or repeated laxatives.
When is abdominal discomfort an emergency?
Severe, persistent, or worsening abdominal discomfort—especially with vomiting, radiation to the back, fever, jaundice, major swelling, or inability to pass stool/gas—requires stopping the medication and urgent emergency evaluation.
What if my vision changes?
Stop the medication and obtain immediate emergency eye or emergency-department evaluation for sudden loss, a curtain/dark area, or a major acute change. Do not wait for a routine appointment.
Do GLP-1 drugs cause thyroid cancer?
They caused C-cell tumors in rodents. It is unknown whether they cause MTC in humans. Current labels contraindicate use with personal or family MTC or MEN2 history.
Can I use a GLP-1 if I had pancreatitis?
Prior pancreatitis is not written as a universal absolute contraindication in every label, but it is an important recurrence concern. APNS may exclude treatment or require specialist evaluation depending on cause and history.
Can I use a GLP-1 with constipation or IBS-C?
Mild stable constipation may be manageable, but severe chronic constipation, slow-transit disease, ileus, obstruction, or significant motility symptoms may make treatment unsafe. Individual review is required.
Does diabetic retinopathy make me ineligible?
Not automatically. Rapid glucose improvement can temporarily worsen retinopathy, so coordinated eye monitoring may be needed. Sudden vision change is an emergency.
Can GLP-1 medicines treat fatty liver?
Weight loss can improve MASLD, and Wegovy now has an FDA indication for selected adults with noncirrhotic MASH and moderate-to-advanced fibrosis. Liver disease still requires proper evaluation.
Are compounded GLP-1 medicines the same as Wegovy or Zepbound?
No. Compounded products are not FDA-approved generic equivalents and may use different concentrations, dosage forms, excipients, or ingredients. Their safety, effectiveness, and bioequivalence are not established by FDA review.
Is compounded oral semaglutide the same as oral Wegovy?
No. FDA-approved oral Wegovy is a specific 25 mg tablet with specific administration and trial data. Drops, troches, sprays, or other compounded formulations should not be assumed to work the same way.
Will medication work without changing my eating or activity?
Medication can reduce biological hunger, but nutrition, movement, strength training, sleep, and behavior remain important for health, muscle preservation, and long-term maintenance. Extreme dieting is not required or recommended.
Should everyone use intermittent fasting?
No. Some patients find time-restricted eating useful; others develop dizziness, hypoglycemia, binge eating, reflux, or inadequate protein. The approach must fit the patient and medications.
Will I lose muscle?
Some lean mass is lost during most substantial weight loss. Adequate protein, resistance training, appropriate rate of loss, and monitoring help preserve muscle.
When should treatment be stopped?
Stop for pregnancy, a serious allergic reaction, suspected pancreatitis, severe GI disease, or another serious adverse event. Change or discontinue when risks outweigh benefits or an adequate therapeutic trial produces no meaningful benefit.
Do I have to stop after 12 months?
No universal 12-month stop rule exists. Many patients need long-term maintenance. The decision should be individualized because stopping often leads to increased hunger and regain.
Can I use a very low dose for maintenance?
Possibly, if the prescriber determines that a lower dose maintains benefit and remains safe. The strongest evidence is for labeled maintenance doses. Nonstandard microdosing or extended intervals are off label and require close monitoring for hunger, regain, side effects, and metabolic changes.
What happens if I regain weight?
Regain is common biology, not failure. The plan may be adjusted by reviewing nutrition, activity, sleep, medications, dose, another anti-obesity therapy, or metabolic surgery.
Does APNS prescribe phentermine?
No. Phentermine is a controlled substance. APNS does not prescribe, refill, or manage controlled substances.
Patient Notice
This information is educational and does not replace individualized medical care. Medication eligibility, dosing, monitoring, and emergency decisions depend on the specific product and the patient’s health history. Do not share medication, alter a compounded concentration, or increase a dose without prescriber instructions.
Ready to take the next step?
Whether you’re just beginning your weight loss journey or looking for additional support after previous attempts, APNS is here to help. Our providers will work with you to develop a personalized treatment plan based on your health, goals, and individual needs.